2022 SHS Professor Li Jianyong: Li Chaotou, talk about treatment options for primary central nervous system lymphoma, step on the waves, and discuss the current situation of blood development in Jiangsu

The much-anticipated "2022 Suzhou Hematology Summit and National Continuing Medical Education Class" was grandly opened
in Suzhou on October 7-9, 2022.
The conference invited well-known hematology experts at home and abroad to conduct in-depth discussions
on the research and development of new hematology drugs, precision medicine and leukemia, big data platform construction, and blood innovation forum.
On this occasion, Yimaitong specially invited Professor Li Jianyong of Jiangsu Provincial People's Hospital to be interviewed to introduce us to the treatment strategy of primary central nervous system lymphoma (PCNSL) and talk about the development status
of blood in Jiangsu.

Yimaitong: Based on your clinical experience, can you introduce what are the current treatment strategies for PCNSL patients in China? And what are the new drug advances in the field of PCNSL?

PCNSL is rare, accounting for only about
1% of all lymphomas.
As a result, PCNSL is not as much attention
as diffuse large B-cell lymphoma (DLBCL).
It was not until 2021 that the "Chinese Central Nervous System Lymphoma Working Group" was officially established
.
Jointly initiated by the Neurosurgery Branch of the Chinese Medical Association and the Hematology and Oncology Professional Committee of the Chinese Anti-Cancer Association, led by President Mao Ying and Professor Chen Tong of Huashan Hospital affiliated to Fudan University, together with more than 40 experts in China, the "Chinese Expert Consensus on Clinical Practice of Primary Central Nervous System Lymphoma Based on Evidence" was recently published in the international authoritative journal Journal of Hematology & Oncology
.
The formulation of this consensus has important guiding significance
for the standardized diagnosis and treatment and follow-up of PCNSL.

PCNSL is highly aggressive and has a poor prognosis, and high-dose methotrexate (HD-MTX) is currently the mainstay
of PCNSL treatment.
For first-line treatment in younger patients, high-dose cytarabine or CD20 monoclonal antibody can be used in combination with HD-MTX to further improve efficacy
.
When a patient achieves complete or partial remission (PR) after first-line therapy, autologous hematopoietic stem cell transplantation (allo-HSCT) is used for consolidation therapy
.
Older patients can be treated
with temozolomide.
In addition, radiation therapy is also of great value in the treatment of PCNSL, especially in patients
who do not achieve CR or who are relapsed/refractory.

In recent years, new drugs in the field of PCNSL have been emerging
.
Among them, the most concerned is BTK inhibitors (ibrutinib, zebrutinib, aclotinib, etc.
), BTK inhibitors in China have high accessibility and short-term efficacy is very good
.
In addition, PD-1 monoclonal antibodies (nivolumab, etc.
), XPO1 inhibitors (cerinisole), and immunomodulators (pomalidomide, etc.
) have also been advanced
in PCNSL therapy.
In general, China's current PCNSL treatment drugs have a large choice of choices, and new drug research on PCNSL is still being explored
.

Yimaitong: Jiangsu Provincial People's Hospital and the First Affiliated Hospital of Soochow University are both prominent representatives of the field of hematology in Jiangsu Province, can you tell us about the achievements and contributions of Jiangsu Blood in the field?

In general, under the leadership of generations of hematology experts such as Professor Chen Yueshu, Academician Ruan Changgeng, Professor Wu Depei and the Suzhou blood team, Jiangsu Blood has taken a leading position in the field of hematology in China, and its status is gradually improving
.
Jiangsu Provincial People's Hospital and the First Affiliated Hospital of Soochow University are prominent representatives in the field of blood in Jiangsu Province, and the two hospitals have their own characteristics
in the diagnosis and treatment of blood diseases.

The First Affiliated Hospital of Soochow University is one of the first national clinical medical research centers for hematological diseases established in China, featuring thrombosis hemostasis and hematopoietic stem cell transplantation, is a first-class blood disease diagnosis and treatment center in China, and also has a very important position
in the world.
CAR-T is currently one of the most advanced therapies in the treatment of hematological malignancies in the world, and up to now, the First Affiliated Hospital of Soochow University has carried out CAR-T cell therapy is estimated to have exceeded 1,000 cases
.

The First Affiliated Hospital of Soochow University has made good explorations in lymphoma, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and multiple myeloma (MM) and other hematological diseases, for example, Professor Tang Xiaowen has presided over a number of acute leukemia-related scientific research projects, which has made a non-negligible contribution to the progress of acute leukemia diagnosis and treatment in China; Professor Fu has participated in and presided over more than 30 clinical studies
of new MM drugs internationally, Asia-Pacific and domestically.
The First Affiliated Hospital of Soochow University has "fully blossomed"
in the exploration of new drugs for hematological diseases and blood-related diseases such as mastocytosis.

In the overall diagnosis and treatment of hematological diseases, there is still a certain gap
between Jiangsu Provincial People's Hospital and the First Affiliated Hospital of Soochow University.
Jiangsu Provincial People's Hospital mainly features the diagnosis and treatment of lymphoma such as chronic lymphoblastic leukemia (CLL) and the diagnosis and treatment of elderly AML patients, and is the first medical center in China to use demethylation drugs combined with chemotherapy for elderly AML patients, and the program has been widely used in clinical practice
.
Not only that, Jiangsu Provincial People's Hospital has also carried out more clinical trials
of MM and lymphoma-related CAR-T cells.

Professor Li Jianyong

• Jiangsu Provincial People's Hospital

• Class A Distinguished Professor, Director of Hematology, Doctoral Supervisor, Postdoctoral Co-supervisor

• Member of the Standing Committee of the Hematology Branch of the Chinese Medical Association, Head of the Lymphocytic Disease Group

• Chairman of the Fourth Hematology and Oncology Professional Committee of the Chinese Anti-Cancer Association

• Vice Chairman of the Lymphoma Quality Control Expert Committee of the National Cancer Quality Control Center

• Leader of the Chinese Working Group on Chronic Lymphocytic Leukemia

• Vice Chair of the CSCO Lymphoma Expert Committee

• Deputy head of the Lymphoma Group of the Oncology Branch of the Chinese Medical Association

• Chairman of the Hematology Branch of Jiangsu Geriatrics Association

• President-elect of Hematologist Branch of Jiangsu Medical Association

• Chairman of the 7th Hematology Branch of Jiangsu Medical Association

• Chairman of the Hematology Branch of Nanjing Medical Association

• Vice Chairman of China Hematology Specialist Alliance

• Vice Chairman of Hematology Institution Branch of Chinese Hospital Association